2024 annual financial data
Scribe Therapeutics 2024 Operating margin
Scribe Therapeutics 2024 operating margin with verified reported values.
Direct answer
Operating margin was -156.24%.
Operating income was -42,829,000 USD and net income was -47,786,000 USD.
Operating cash flow was -45,235,000 USD.
Get free Scribe Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 27,413,000 USD
- Operating income
- -42,829,000 USD
- Net income
- -47,786,000 USD
- Operating cash flow
- -45,235,000 USD